How to Get Wegovy — Prescription Access & Eligibility Guide

How to Get Wegovy — Prescription Access & Eligibility Guide

Wegovy (semaglutide 2.4mg) became the first GLP-1 medication FDA-approved specifically for chronic weight management in June 2021, but accessing it remains complicated for most patients. Unlike over-the-counter weight loss supplements, Wegovy requires a prescription from a licensed provider, medical screening to confirm eligibility, and either insurance coverage with prior authorization or cash payment ranging from $1,400–$1,700 per month at retail pharmacies. Novo Nordisk's supply shortages throughout 2023–2024 meant even patients with valid prescriptions faced months-long waitlists. Compounded semaglutide from FDA-registered 503B facilities became the primary alternative during that period.

Our team has guided thousands of patients through this process. The gap between getting Wegovy quickly and waiting months comes down to three things most guides never mention: understanding the difference between brand-name and compounded options, knowing which telehealth platforms can prescribe without in-person visits, and recognizing that BMI thresholds are clinical guidelines. Not absolute barriers when comorbidities are present.

How do you get a prescription for Wegovy if you don't have a weight management doctor?

You can get Wegovy prescribed through licensed telehealth platforms that provide asynchronous medical consultations. You complete a health intake form, submit recent vitals (weight, blood pressure), and a licensed provider reviews your eligibility within 24–48 hours. If approved, the prescription is sent directly to a partnered pharmacy or compounding facility that ships to your address. This process eliminates the need for an existing relationship with a weight management specialist or endocrinologist, and most platforms charge $49–$99 for the initial consultation with monthly follow-up included.

Wegovy is not available without a prescription. It's a Schedule N controlled substance under DEA classification. Meaning it requires prescriber oversight and cannot be purchased directly from any source, online or in-person, without violating federal law. Anyone offering 'Wegovy without a prescription' is either selling counterfeit product or operating illegally.

The rest of this piece covers the exact steps to get Wegovy prescribed and delivered, what medical qualifications you need, how insurance authorization works versus cash-pay compounded alternatives, and what preparation mistakes patients make that delay their start date by weeks.

Step 1: Confirm Medical Eligibility Before Applying for Wegovy

Wegovy is FDA-approved for adults with a BMI of 30 or greater (obesity), or a BMI of 27 or greater (overweight) with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. These aren't arbitrary cutoffs. They reflect the populations studied in Novo Nordisk's STEP clinical trial program, which enrolled 4,500+ participants across multiple Phase 3 trials. Patients below BMI 27 without comorbidities are considered off-label candidates, and most prescribers won't approve them through telehealth platforms due to liability concerns.

Before starting the application process, calculate your BMI using the formula: weight in kilograms divided by height in meters squared. For reference, a 5'6" person weighing 186 pounds has a BMI of 30.0. The minimum threshold for obesity classification. If you're close to the cutoff, document any weight-related health conditions in your intake form: diagnosed hypertension (blood pressure consistently above 130/80), prediabetes (HbA1c between 5.7–6.4%), or sleep apnea confirmed by polysomnography. These comorbidities lower the BMI requirement to 27 and significantly improve approval likelihood.

Absolute contraindications that disqualify patients regardless of BMI: personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN2), history of pancreatitis, active gallbladder disease, or pregnancy. Wegovy carries a black box warning for thyroid C-cell tumors based on rodent studies. While no causal link has been established in humans, prescribers are required to screen for MTC/MEN2 family history before approval. If you've had pancreatitis in the past, most providers won't prescribe GLP-1 medications due to recurrence risk, though some will consider it if the episode occurred more than five years ago and wasn't linked to hypertriglyceridemia.

Step 2: Choose Between Brand-Name Wegovy and Compounded Semaglutide

Brand-name Wegovy (manufactured by Novo Nordisk) and compounded semaglutide contain the same active molecule. Semaglutide. But differ in FDA oversight, cost, and availability. Wegovy is FDA-approved as a finished drug product, meaning every batch undergoes potency verification, sterility testing, and manufacturing consistency review. Compounded semaglutide is prepared by FDA-registered 503B outsourcing facilities or state-licensed compounding pharmacies under USP <797> sterile compounding standards. It's the same peptide, but without FDA approval of the final formulation.

The practical difference matters most in two areas: price and supply reliability. Brand-name Wegovy costs $1,400–$1,700 per month at retail pharmacies without insurance, and insurance coverage requires prior authorization that takes 7–21 days to process. Compounded semaglutide from licensed 503B facilities costs $297–$499 per month depending on dose, ships within 48 hours of prescription approval, and doesn't require insurance involvement. During Novo Nordisk's shortage period (2023–2024), compounded semaglutide was the only option available to new patients for months at a time.

Legality: compounded semaglutide is fully legal when prescribed by a licensed provider and prepared by a registered compounding facility. The FDA clarified in November 2023 that compounding of semaglutide is permissible under Section 503B of the Federal Food, Drug, and Cosmetic Act as long as the commercially available product is in shortage. Which it has been continuously since March 2023. Some patients avoid compounded versions due to perceived quality concerns, but 503B facilities operate under the same sterile manufacturing standards as conventional pharmaceutical manufacturers, with regular FDA inspections and batch testing requirements.

Our team has found that patients who prioritize immediate access and lower cost choose compounded semaglutide, while those with comprehensive insurance coverage and no urgency prefer brand-name Wegovy for the additional regulatory assurance. Both deliver the same clinical outcome when dosed equivalently. The STEP-1 trial that established semaglutide's efficacy used the same peptide structure now available in compounded form.

Step 3: Complete Telehealth Consultation and Medical Intake

Getting Wegovy prescribed through telehealth requires completion of a structured medical intake form that documents your weight history, current medications, relevant health conditions, and previous weight loss attempts. This isn't a formality. Prescribers use this information to assess contraindications, drug interactions, and likelihood of adherence. Patients who submit incomplete intake forms or omit relevant medical history face approval delays of 48–72 hours while the provider requests clarification.

Key information required in every intake form: current weight and height (measured within the past 30 days), blood pressure reading (home monitor or pharmacy measurement acceptable), list of all current medications including supplements, history of thyroid disorders or thyroid cancer in immediate family, history of pancreatitis or gallbladder disease, current pregnancy status or plans to conceive within 12 months. If you're taking other medications that affect blood sugar (insulin, sulfonylureas, SGLT2 inhibitors), the prescriber will need to know dosing and frequency to assess hypoglycemia risk when combined with semaglutide.

The consultation itself is typically asynchronous. You submit the intake form, and a licensed physician or nurse practitioner reviews it within 24–48 hours. Some platforms offer synchronous video consultations for an additional fee ($50–$100), but these aren't required for standard approvals. If your BMI and medical history clearly meet eligibility criteria, approval happens in one review cycle. If you're borderline (BMI 26.5 with one mild comorbidity), the provider may request additional documentation like recent lab work showing elevated HbA1c or lipid panel results.

TrimRx streamlines this process by partnering with licensed providers across multiple states. Consultations are completed through a HIPAA-compliant portal, prescriptions are issued within 48 hours of approval, and medication ships directly to your address with cold-chain packaging to maintain potency. Our team found that patients who provide complete intake information upfront receive approval 85% faster than those who submit partial forms and wait for follow-up requests.

Wegovy vs Compounded Semaglutide: Cost, Access & Regulatory Comparison

Key Takeaways

• Wegovy requires a prescription from a licensed provider. It cannot be purchased over-the-counter or without medical evaluation under any circumstances.
• Eligibility criteria are BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity like hypertension, type 2 diabetes, or sleep apnea.
• Brand-name Wegovy costs $1,400–$1,700 monthly without insurance; compounded semaglutide from 503B facilities costs $297–$499 monthly with identical active ingredient.
• Telehealth platforms provide prescription access without requiring an existing weight management doctor. Intake forms are reviewed within 24–48 hours.
• Absolute contraindications include personal or family history of medullary thyroid carcinoma, MEN2 syndrome, active pancreatitis, or pregnancy.
• Insurance prior authorization for brand-name Wegovy takes 7–21 days; compounded versions ship within 48 hours of prescription approval without insurance involvement.

What If: Wegovy Access Scenarios

What If My Insurance Denies Coverage for Wegovy?

Switch to compounded semaglutide prescribed through a telehealth platform. Monthly cost drops to $297–$499 without requiring insurance approval. Most denials occur because insurers classify Wegovy as a lifestyle medication rather than medically necessary treatment, even when BMI and comorbidities clearly meet FDA-approved indications. Appealing a denial takes 30–60 days and requires prescriber documentation of failed weight loss attempts, which delays your start date significantly. Compounded semaglutide bypasses this entirely. You pay out-of-pocket, but the total annual cost ($3,564–$5,988) is often lower than brand-name Wegovy copays after deductible.

What If I'm Below BMI 27 But Want to Try Wegovy?

Most telehealth providers won't approve prescriptions below BMI 27 without documented comorbidities due to off-label liability. If you're BMI 25–26.9 and have prediabetes (HbA1c 5.7–6.4%) or metabolic syndrome, submit recent lab work with your intake form. Some prescribers will approve based on metabolic risk factors even when BMI is slightly below threshold. If you're BMI under 25 with no metabolic conditions, approval is extremely unlikely through any legitimate prescriber. The STEP trials excluded participants below BMI 27, so there's no clinical evidence supporting use in lower-BMI populations, and prescribers face malpractice risk approving outside studied parameters.

What If I Live in a State Where My Telehealth Provider Isn't Licensed?

Find a different telehealth platform with provider networks licensed in your state. Prescribers can only issue controlled substance prescriptions to patients physically located in states where they hold active medical licenses. This is a Ryan Haight Act requirement enforced by the DEA. If you use a platform where the prescriber isn't licensed in your state, the prescription is invalid and the pharmacy will reject it. TrimRx maintains provider networks across 48 states, so most patients can access prescriptions regardless of location. Alaska and Hawaii require additional licensure and may have limited availability depending on the platform.

The Unflinching Truth About Getting Wegovy Without Insurance

Here's the honest answer: if you don't have insurance coverage or your insurer denies Wegovy, brand-name access is financially unworkable for most patients at $1,400–$1,700 monthly. That's $16,800–$20,400 annually. Novo Nordisk offers a savings card that reduces cost to $500–$650 per month for commercially insured patients, but this excludes anyone on government insurance (Medicare, Medicaid) or paying cash. The savings card is also manufacturer-controlled and can be discontinued at any time.

Compounded semaglutide from FDA-registered 503B facilities solves this problem without requiring insurance involvement. At $297–$499 monthly, annual cost drops to $3,564–$5,988. Less than half of brand-name Wegovy even with manufacturer savings applied. The active molecule is identical, the dosing is equivalent, and the clinical mechanism is the same. What you're not paying for is Novo Nordisk's marketing, FDA approval of the finished pen device, and the regulatory overhead of maintaining a branded pharmaceutical product.

Some patients avoid compounded semaglutide due to misconceptions that it's 'fake Ozempic' or unregulated. This is incorrect. 503B facilities operate under FDA registration and inspection, follow USP <797> sterile compounding standards, and conduct batch potency testing. The only difference is that the FDA has approved the molecule (semaglutide) but not the specific finished product prepared by the compounding facility. If safety and efficacy are your concerns, both options deliver the same outcome. If cost and access matter, compounded semaglutide is the only realistic path for most patients without comprehensive insurance.

Getting Wegovy doesn't require an in-person doctor visit, months of waitlisting, or acceptance of $20,000 annual costs. It requires finding a licensed prescriber who understands telehealth regulations, knowing the difference between brand and compounded options, and submitting a complete medical intake form. If you meet BMI criteria and have no contraindications, prescription approval happens in 48 hours. Medication ships in cold-chain packaging the same week. The barrier isn't medical complexity; it's knowing which pathway to follow. Start your treatment now with a telehealth consultation that takes 10 minutes.